AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25830322 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV vaccine (20 million PFU or 100 million PFU)
Number of subjects: 78
Study 25830322 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV vaccine (second dose at day 28)
Number of subjects: 78
Study 25830322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 25830322 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV vaccine
Number of subjects: 78
Study 26655169 — intervention group
Group type: EXPERIMENTAL
Intervention: Single running suture technique
Number of subjects: 162
Study 24527419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counseling (2 sessions + 1 cooking class)
Number of subjects: 61
Study 24527419 — intervention group
Group type: COMPARATOR
Intervention: Standard care (brochures recommending phytochemical rich diet)
Number of subjects: 61
Study 20865423 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (ECC group)
Number of subjects: 24
Study 20865423 — intervention group
Group type: COMPARATOR
Intervention: Concentric exercise (CON group)
Number of subjects: 24
Study 19034471 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mug misoprostol intravaginally every 4 h to a maximum of five doses
Number of subjects: 112
Study 19034471 — intervention group
Group type: COMPARATOR
Intervention: 10 mg dinoprostone vaginal insert for a maximum of 12 h
Number of subjects: 112
Study 17523399 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicor (a long‐action garlic‐based preparation) administered for 12 months
Number of subjects: 51
Study 17523399 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicor (a long‐action garlic‐based preparation)
Number of subjects: 51
Study 15342615 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levosimendan 2 to 8 mg daily
Number of subjects: 25
Study 15342615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11532109 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 1860
Study 11532109 — intervention group
Group type: COMPARATOR
Intervention: Control (non-ACE inhibitor regimens)
Number of subjects: 1860
Study 9778329 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 603
Study 9778329 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy in NYHA class I
Number of subjects: 603
Study 9778329 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy in NYHA class II
Number of subjects: 603
Study 9778329 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy in NYHA class III
Number of subjects: 603
Study 8201808 — intervention group
Group type: EXPERIMENTAL
Intervention: Comics, photos, and poems to induce emotion
Number of subjects: 1220
Study 8201808 — intervention group
Group type: EXPERIMENTAL
Intervention: General emotional intensity scale
Number of subjects: 1220
Study 3297521 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant positive airway pressure (CPAP) with an expiratory pressure of 12 cm H2O applied at one hour following extubation, and at daily intervals for the first five days following surgery for a continuous period of three hours
Number of subjects: 34
Study 3297521 — intervention group
Group type: COMPARATOR
Intervention: No CPAP treatment
Number of subjects: 34
Study 2201225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg intramuscularly followed by 10 mg 4-hourly as required
Number of subjects: 80
Study 2201225 — intervention group
Group type: COMPARATOR
Intervention: Morphine 10 mg intramuscularly 4-hourly as required
Number of subjects: 80
Study 2201225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 80
Study 2201225 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 80
Study 12114 — intervention group
Group type: EXPERIMENTAL
Intervention: fominoben
Number of subjects: 12
Study 12114 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 31387559 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) and lung ultrasound (LUS)-guided antibiotic therapy
Number of subjects: 100
Study 31387559 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) only-guided therapy
Number of subjects: 100
Study 31387559 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 28203001 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone graft therapy combined with CGFs
Number of subjects: 31
Study 28203001 — intervention group
Group type: COMPARATOR
Intervention: Bone graft therapy alone
Number of subjects: 31
Study 26047890 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmirtazapine 1.5 mg
Number of subjects: 526
Study 26047890 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmirtazapine 3.0 mg
Number of subjects: 526
Study 26047890 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmirtazapine 4.5 mg
Number of subjects: 526
Study 26047890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 526
Study 26047890 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmirtazapine (all doses)
Number of subjects: 526
Study 23291105 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vaccine
Number of subjects: 0
Study 23291105 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vaccine
Number of subjects: 0
Study 23291105 — intervention group
Group type: COMPARATOR
Intervention: PBS control
Number of subjects: 0
Study 23291105 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant control
Number of subjects: 0
Study 21692409 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal steroid injection (triamcinolone acetonide 20 mg)
Number of subjects: 19
Study 21692409 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal steroid injection (triamcinolone acetonide 20 mg)
Number of subjects: 19
Study 21692409 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study 21692409 — intervention group
Group type: EXPERIMENTAL
Intervention: NCS (nerve conduction studies)
Number of subjects: 19
Study 19058842 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic drugs (amisulpride, clozapine, olanzapine, risperidone)
Number of subjects: 21533
Study 19058842 — intervention group
Group type: COMPARATOR
Intervention: Second-generation antipsychotic drugs
Number of subjects: 21533
Study 16436844 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen tube
Number of subjects: 66
Study 16436844 — intervention group
Group type: EXPERIMENTAL
Intervention: Univent tube
Number of subjects: 66
Study 16436844 — intervention group
Group type: EXPERIMENTAL
Intervention: Arndt Blocker
Number of subjects: 66
Study 14969634 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded assessment of the carotid pulse by cardiologists
Number of subjects: 46
Study 14969634 — intervention group
Group type: EXPERIMENTAL
Intervention: Applanation tonometry on the radial pulse
Number of subjects: 46
Study 14969634 — intervention group
Group type: EXPERIMENTAL
Intervention: Applanation tonometry on the carotid pulse
Number of subjects: 46
Study 11401629 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% atropine with multi‐focal glasses
Number of subjects: 227
Study 11401629 — intervention group
Group type: EXPERIMENTAL
Intervention: multi‐focal glasses
Number of subjects: 227
Study 11401629 — intervention group
Group type: COMPARATOR
Intervention: single vision spectacles
Number of subjects: 227
Study 9099195 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 3127
Study 9099195 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose aspirin
Number of subjects: 3127
Study 9099195 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (low-dose and medium-dose aspirin)
Number of subjects: 3127
Study 8135165 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture point SP-10
Number of subjects: 0
Study 8135165 — intervention group
Group type: COMPARATOR
Intervention: Non-acupuncture point
Number of subjects: 0
Study 3104964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine pretreatment
Number of subjects: 0
Study 3104964 — intervention group
Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 0
Study 31456496 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephonic intervention
Number of subjects: 21971
Study 31456496 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 21971
Study 31456496 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephonic intervention (among those who completed the call)
Number of subjects: 21971
Study 28064421 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling about sleep location emphasizing safe sleep practices to reduce SIDS risk
Number of subjects: 1194
Study 28064421 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling about sleep location emphasizing safe sleep practices to prevent SIDS/suffocation
Number of subjects: 1194
Study 28064421 — intervention group
Group type: COMPARATOR
Intervention: Group assignment (intervention vs control)
Number of subjects: 1194
Study 25303950 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupuncture point stimulation (TEAS)
Number of subjects: 68
Study 25303950 — intervention group
Group type: COMPARATOR
Intervention: Mock TEAS
Number of subjects: 68
Study 23992438 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath Powered™ nasal delivery of 16-mg sumatriptan powder
Number of subjects: 20
Study 23992438 — intervention group
Group type: COMPARATOR
Intervention: 20-mg liquid nasal spray
Number of subjects: 20
Study 23992438 — intervention group
Group type: COMPARATOR
Intervention: 100-mg oral tablet
Number of subjects: 20
Study 23992438 — intervention group
Group type: COMPARATOR
Intervention: 6-mg subcutaneous injection
Number of subjects: 20
Study 20971632 — intervention group
Group type: EXPERIMENTAL
Intervention: mIROX (irinotecan plus oxaliplatin 85 mg/m(2))
Number of subjects: 479
Study 20971632 — intervention group
Group type: COMPARATOR
Intervention: FUFIRI (irinotecan 80 mg/m(2), 5‐fluorouracil 2000 mg/m(2), folinic acid 500 mg/m(2) weekly times 6)
Number of subjects: 479
Study 20971632 — intervention group
Group type: EXPERIMENTAL
Intervention: mIROX
Number of subjects: 479
Study 20971632 — intervention group
Group type: COMPARATOR
Intervention: FUFIRI
Number of subjects: 479
Study 18983928 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose theophylline
Number of subjects: 26
Study 18983928 — intervention group
Group type: COMPARATOR
Intervention: Tulobuterol
Number of subjects: 26
Study 17194276 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 to 60 mg/day
Number of subjects: 28
Study 17194276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12094123 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g Cr.H2O
Number of subjects: 8
Study 12094123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10459398 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture with tryptophan (TRP)
Number of subjects: 27
Study 10459398 — intervention group
Group type: COMPARATOR
Intervention: Amino acid mixture without tryptophan (placebo)
Number of subjects: 27
Study 7572251 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily lithium dosing (800 mg/day)
Number of subjects: 50
Study 7572251 — intervention group
Group type: COMPARATOR
Intervention: Every second day lithium dosing (1200 mg/every second day)
Number of subjects: 50
Study 1971170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirol 0.4 mg
Number of subjects: 8
Study 1971170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirol 0.8 mg
Number of subjects: 8
Study 1971170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirol 1 mg
Number of subjects: 8
Study 1971170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirol (all doses)
Number of subjects: 8
Study 1971170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 33376 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5‐10 mg)
Number of subjects: 32
Study 33376 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.4‐0.8 mg)
Number of subjects: 32
Study 33376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29925498 — intervention group
Group type: EXPERIMENTAL
Intervention: Show Me Health Plans tool
Number of subjects: 1069
Study 27460104 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel device for ETT cleaning used every 8 hours
Number of subjects: 74
Study 27460104 — intervention group
Group type: COMPARATOR
Intervention: Institutional standard of care (blind tracheal suction)
Number of subjects: 74
Study 27460104 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel device for ETT cleaning
Number of subjects: 74
Study 24352342 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10% RLP068
Number of subjects: 62
Study 24352342 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30% RLP068
Number of subjects: 62
Study 24352342 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50% RLP068
Number of subjects: 62
Study 24352342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 22281412 — intervention group
Group type: EXPERIMENTAL
Intervention: Varespladib
Number of subjects: 31
Study 22281412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 20871948 — intervention group
Group type: COMPARATOR
Intervention: Ca(OH)₂ paste
Number of subjects: 30
Study 20871948 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitapex paste
Number of subjects: 30
Study 17458641 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine continuous epidural infusion with clonidine (5 microg.ml(‐1))
Number of subjects: 68
Study 17458641 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine continuous epidural infusion without clonidine (control group)
Number of subjects: 68
Study 17458641 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine continuous epidural infusion with clonidine
Number of subjects: 68
Study 15450693 — intervention group
Group type: EXPERIMENTAL
Intervention: Written disclosure intervention (participants wrote each week for 3 weeks)
Number of subjects: 35
Study 15450693 — intervention group
Group type: COMPARATOR
Intervention: Control writing group
Number of subjects: 35
Study 15450693 — intervention group
Group type: EXPERIMENTAL
Intervention: Written disclosure intervention
Number of subjects: 35
Study 12021091 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 0
Study 10450120 — intervention group
Group type: EXPERIMENTAL
Intervention: Legs crossed (method 1)
Number of subjects: 103
Study 10450120 — intervention group
Group type: EXPERIMENTAL
Intervention: Legs crossed (method 2)
Number of subjects: 103
Study 7503082 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 8
Study 7503082 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 8
Study 2190005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 20
Study 2190005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 474042 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg cyproterone acetate
Number of subjects: 8
Study 474042 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cyproterone acetate
Number of subjects: 8
Study 474042 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 months prior to treatment)
Number of subjects: 8
Study 28716014 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS care model
Number of subjects: 6000
Study 28716014 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6000
Study 25666010 — intervention group
Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 37
Study 25666010 — intervention group
Group type: EXPERIMENTAL
Intervention: White mineral trioxide aggregate (MTA)
Number of subjects: 37
Study 25261291 — intervention group
Group type: EXPERIMENTAL
Intervention: lipegfilgrastim 6.0 mg
Number of subjects: 208
Study 25261291 — intervention group
Group type: COMPARATOR
Intervention: pegfilgrastim 6.0 mg
Number of subjects: 208
Study 22811596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin ER tablet 80 mg QD
Number of subjects: 20
Study 22811596 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin IR capsule 40 mg BID
Number of subjects: 20
Study 19238124 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 15-30 mg/day
Number of subjects: 0
Study 19238124 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 10-15 mg/day
Number of subjects: 0
Study 17475739 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped treatment initiated with buprenorphine/naloxone
Number of subjects: 96
Study 17475739 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance therapy
Number of subjects: 96
Study 17475739 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped treatment and Methadone maintenance therapy
Number of subjects: 96
Study 15022801 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate weight-bearing (I)
Number of subjects: 20
Study 15022801 — intervention group
Group type: COMPARATOR
Intervention: Late weight-bearing (L)
Number of subjects: 20
Study 12500987 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg(‐1) before exercise and 0.33 mg.kg(‐1) every 15 min during exercise)
Number of subjects: 8
Study 12500987 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 8
Study 12500987 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (Cho)
Number of subjects: 8
Study 12500987 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (Caf)
Number of subjects: 8
Study 9536227 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 micrograms/g) applied twice daily
Number of subjects: 135
Study 9536227 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle only) applied twice daily
Number of subjects: 135
Study 9536227 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 micrograms/g) with acitretin
Number of subjects: 135
Study 9536227 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin therapy
Number of subjects: 135
Study 2051728 — intervention group
Group type: EXPERIMENTAL
Intervention: Different combinations of dialysate and substitution fluids
Number of subjects: 0
Study 2051728 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate containing substitution fluid
Number of subjects: 0
Study 6420609 — intervention group
Group type: EXPERIMENTAL
Intervention: hpGRF1-44 at 3.3 micrograms
Number of subjects: 8
Study 6420609 — intervention group
Group type: EXPERIMENTAL
Intervention: hpGRF1-44 at 12.5 micrograms
Number of subjects: 8
Study 6420609 — intervention group
Group type: EXPERIMENTAL
Intervention: hpGRF1-44 at 50 micrograms
Number of subjects: 8
Study 6420609 — intervention group
Group type: EXPERIMENTAL
Intervention: hpGRF1-44 at 100 micrograms
Number of subjects: 8
Study 6420609 — intervention group
Group type: EXPERIMENTAL
Intervention: hpGRF1-44 at 200 micrograms
Number of subjects: 8
Study 6420609 — intervention group
Group type: EXPERIMENTAL
Intervention: hpGRF1-44 (all dosages except 3.3 micrograms)
Number of subjects: 8
Study 6420609 — intervention group
Group type: EXPERIMENTAL
Intervention: hpGRF1-44 (200 micrograms)
Number of subjects: 8
Study 6420609 — intervention group
Group type: EXPERIMENTAL
Intervention: hpGRF1-44 (3.3 to 50 micrograms)
Number of subjects: 8
Study 6420609 — intervention group
Group type: EXPERIMENTAL
Intervention: hpGRF1-44 (up to 200 micrograms)
Number of subjects: 8
Study 6420609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30678197 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenutrition weight loss intervention with weekly support from a registered dietitian nutritionist via telephone and videoconferencing
Number of subjects: 59
Study 30678197 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 59
Study 28367771 — intervention group
Group type: EXPERIMENTAL
Intervention: Step stool use
Number of subjects: 124
Study 28367771 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted height
Number of subjects: 124
Study 28367771 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 124
Study 28367771 — intervention group
Group type: EXPERIMENTAL
Intervention: JIT CPR training
Number of subjects: 124
Study 26762723 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA-guided decision making (R-II)
Number of subjects: 647
Study 26762723 — intervention group
Group type: COMPARATOR
Intervention: Standard care (R-I)
Number of subjects: 647
Study 24594505 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (21 mg capsules with 250 mL of full-cream milk per day for 4 weeks)
Number of subjects: 44
Study 24594505 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with 250 mL of full-cream milk per day for 4 weeks)
Number of subjects: 44
Study 24594505 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein
Number of subjects: 44
Study 22510023 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HbA(1c) 39-46 mmol/mol (5.7-6.4%) and fasting plasma glucose 5.6-6.9 mmol/l
Number of subjects: 6241
Study 22510023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-diabetic individuals fulfilling HbA(1c) 42-46 mmol/mol (6.0-6.4%) and fasting plasma glucose 6.1-6.9 mmol/l
Number of subjects: 6241
Study 22510023 — intervention group
Group type: EXPERIMENTAL
Intervention: Any of the four combined criteria for pre-diabetes
Number of subjects: 6241
Study 20199960 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fecal immunochemical test (FIT) for CRCS provided on 17 dates.
Number of subjects: 133
Study 20199960 — intervention group
Group type: COMPARATOR
Intervention: CRCS education and encouragement to obtain screening from primary care clinician provided on 5 dates.
Number of subjects: 133
Study 18207280 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy (n=14)
Number of subjects: 30
Study 18207280 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) plus placebo monotherapy (n=16)
Number of subjects: 30
Study 15871887 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Incidental Training (FIT)
Number of subjects: 64